Environmental Permits - Requirements for Burden Analysis, Issuance and Renewal, and Public Participation (Cumulative Harms for Environmental Restoration for Improving Shared Health - CHERISH Our Communities Act)
Summary
House Bill 1268 would require certain Maryland health insurers, nonprofit health service plans, and health maintenance organizations to cover long-term antibiotic treatment for Lyme disease and related tick-borne illnesses when prescribed by a licensed treating physician for therapeutic purposes. The bill defines key terms broadly, including “Lyme disease,” “related tick-borne illness,” “clinical diagnosis,” and “long-term antibiotic treatment,” and it expressly includes treatment based on a physician’s clinical judgment even when the diagnosis does not meet CDC surveillance criteria.
The bill also bars covered entities from imposing quantitative limits on the required treatment and prohibits denial of coverage solely because the treatment is considered unproven, experimental, or investigational. It applies to policies, contracts, and health benefit plans issued, delivered, or renewed in Maryland on or after January 1, 2026.
Impact
If enacted, the bill would add a new section to the Maryland Insurance Article requiring specified carriers and HMOs to cover extended antibiotic regimens for Lyme disease and associated tick-borne illnesses. It would limit insurers’ ability to apply utilization controls or medical-necessity denials based on the treatment’s classification as experimental, and it would expand coverage obligations for plans sold in the state beginning with the 2026 plan year.
Sentiment
No committee transcript or vote record was provided, so there is no documented debate or recorded sentiment in the supplied materials. Based on the bill text alone, the measure appears strongly supportive of expanded access to treatment for patients with Lyme disease and related conditions, with the policy emphasis on physician-directed care and insurance coverage continuity.
Contention
The main likely point of contention is whether insurers should be required to cover long-term antibiotic therapy, especially when the treatment is outside standard surveillance-based Lyme disease criteria or is viewed by payers as unproven or investigational. Supporters would likely emphasize physician discretion and patient access for chronic or persistent symptoms, while opponents may raise concerns about medical evidence, cost, and the appropriateness of mandating coverage for extended antibiotic use.